XML 32 R22.htm IDEA: XBRL DOCUMENT

Collaboration Agreement	6 Months Ended
Collaboration Agreement	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Collaboration Agreement	Collaboration Agreement On September 17, 2020, the Company entered into a strategic collaboration with Affimed GmbH (“Affimed”) to initiate a Phase 1/2 trial of SNK01 in combination with AFM24, a tetravalent biologic created by Affimed designed to direct NK cell killing of epidermal growth factor receptor (“EGFR”) expressing tumors. Under the collaboration agreement, the Company and Affimed split the development costs of the combination product equally, for which Affimed's portion of the shared costs are recognized as a reduction to research and development expenses. The study associated with the strategic collaboration with Affimed was discontinued by mutual agreement in June 2023. Total reductions to research and development expenses for the three and six months ended June 30, 2024 were less than $0.1 million. Total reductions to research and development expenses for the three and six months ended June 30, 2023 were less than $0.1 million and $0.1 million, respectively.